Skip to main content
Erschienen in: Journal of Hematology & Oncology 1/2010

Open Access 01.12.2010 | Letter to the Editor

Acute dyspnoea and single tracheal localisation of mantle cell lymphoma

verfasst von: Jean-Christophe Ianotto, Adrian Tempescul, Jean-Richard Eveillard, Norbert André, Frederic Morel, Isabelle Quintin-Roué, Christian Berthou

Erschienen in: Journal of Hematology & Oncology | Ausgabe 1/2010

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported.

Results

We report here the first case of a unique tracheal localisation of mantle cell lymphoma at presentation of the disease. The presence of classical t(11;14)(q13;q32) confirmed the diagnosis of mantle cell lymphoma by eliminating MALT or cancer localisation.

Conclusion

This case illustrates the necessity to ensure the diagnosis of mucosal lymphoma versus MCL since these diseases need different treatment regimens and prognoses.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1756-8722-3-34) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JCI wrote the paper; AT JRE and CB collected the data and reviewed the paper; NA performed the endoscopic exam; FM did the cytogenetic exam and IQR performed the anatomopathologic exam. All authors read and approved the final manuscript.
Abkürzungen
MALT
Mucosal Associated Lymphoid Tissue
MCL
Mantle Cell Lymphoma.
To the Editor,
We report here an unusual case of a tracheal localisation of mantle cell lymphoma (MCL). The patient was 75-years-old and hospitalized for dyspnoea, dysphonia and stridor, evolving from 3 months. No superficial tumoural syndrome was observed and the patient did not express B-symptoms. The CT-scan showed the presence of an endotracheal tumour of two centimetres under the glottis and two mediastinal centimetric lymph nodes. No other localisations were found. The bronchial endoscopy showed an obstructive vascularised tumour (Figure 1), and the stomach endoscopy was negative. The pneumologist took multiple biopsies and used both laser and endotracheal prothesis to treat the dyspnoea. The anatomo-pathologist identified a massive proliferation of medium to large cells with abundant and clear cytoplasm, round or oval nuclei. Mitosis were observed. Those cells were CD20+/bcl-2+ lymphoid cells with no lymphoepithelial lesions. Cells expressed the CD5+. Many lymphoid cells expressed Cyclin D1 (Monoclonal anti-mouse, clone SP4, Lab Vision). Some CD23+ dendritic cells were observed. CD138 and ALC stains were negative, excluding plasmacytoma and solid tumour. Fluorescence in situ hybridisation of tracheal tumour revealed the presence of a t(11;14)(q13;q32) translocation. We made the diagnosis of MCL. Furthermore, blood and bone marrow exams did not show any abnormal lymphoid B cells with cytological and molecular exams. The patient was treated with four courses of Vincristine-Adriamycin-Dexamethasone-Chloraminophene followed by four injections of Rituximab. We obtained a complete haematological, cytogenetical and isotopic remission. The patient is still alive and in complete remission, 4 years after the diagnosis.
Mantle cell lymphoma is a lymphoid entity defined by clinical, cytological, immunological, biochemical and cytogenetic criteria [1]. One particular entity of MCL, lymphomatoid polyposis, is characterised by the involvement of the gastrointestinal tract (30%), distinct from a mucosal associated lymphoid tissue (MALT) localisation [2, 3]. The frequency of MALT in the trachea is very low; however, nasopharynx and Waldeyer's ring localisations of MCL mimicking MALT have been reported [4, 5]. Dyspnoea was previously described in mediastinal involvement of MCL compressing the trachea [6]. Two cases have been already reported but there were relapse site or one of the multiple localisation of the MCL [7, 8]. This case is different because of its unique localisation and the fact that it is the first evolution of the disease. Because tracheal involment is most seen in cancer and MALT lymphoma with different therapy and evolution, it is important to maximise the chance of an accurate diagnosis by correlating anatomo-pathologist and cytogenetic exams so as not to underestimate the incidence of atypical MCL in cancer/MALT localisation. This case illustrates the necessity to ensure the diagnosis of mucosal lymphoma versus MCL since these diseases have different treatment regimens and prognoses.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JCI wrote the paper; AT JRE and CB collected the data and reviewed the paper; NA performed the endoscopic exam; FM did the cytogenetic exam and IQR performed the anatomopathologic exam. All authors read and approved the final manuscript.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Anhänge

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.
Literatur
1.
Zurück zum Zitat Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Seminars in Hematology. 1999, 36: 115-127.PubMed Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Seminars in Hematology. 1999, 36: 115-127.PubMed
2.
Zurück zum Zitat Rao DS, Said JW: Small lymphoid proliferations in extranodal locations. Archives of Pathology and Laboratory Medicine. 2007, 131: 383-396.PubMed Rao DS, Said JW: Small lymphoid proliferations in extranodal locations. Archives of Pathology and Laboratory Medicine. 2007, 131: 383-396.PubMed
3.
Zurück zum Zitat Okubo K, Miyamoto N, Komaki C: Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the trachea: a case of surgical resection and long term survival. Thorax. 2005, 60: 82-83. 10.1136/thx.2003.018721.PubMedCentralCrossRefPubMed Okubo K, Miyamoto N, Komaki C: Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the trachea: a case of surgical resection and long term survival. Thorax. 2005, 60: 82-83. 10.1136/thx.2003.018721.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S: Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. Journal of Clinical Oncology. 1999, 17: 1254-PubMed Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S: Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. Journal of Clinical Oncology. 1999, 17: 1254-PubMed
5.
Zurück zum Zitat Jaffe ES: Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis. Modern Pathology. 2002, 15: 255-263. 10.1038/modpathol.3880521.CrossRefPubMed Jaffe ES: Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis. Modern Pathology. 2002, 15: 255-263. 10.1038/modpathol.3880521.CrossRefPubMed
6.
Zurück zum Zitat Amemiya M, Takise A, Kaira K, Endou K, Horie T, Inazawa M: Obstructive sleep apnea syndrome in a patient with superior vena cava syndrome caused by malignant lymphoma. Nihon Kokyuki Gakkai Zasshi. 2006, 44: 197-201.PubMed Amemiya M, Takise A, Kaira K, Endou K, Horie T, Inazawa M: Obstructive sleep apnea syndrome in a patient with superior vena cava syndrome caused by malignant lymphoma. Nihon Kokyuki Gakkai Zasshi. 2006, 44: 197-201.PubMed
7.
Zurück zum Zitat Kuppusamy Gounder S, Sikder M, Srinivas S, Chang VT, Kasimis B: Asymptomatic mantle cell lymphoma in the trachea. Leukemia Lymphoma. 2009, 50: 651-652. 10.1080/10428190902718818.CrossRefPubMed Kuppusamy Gounder S, Sikder M, Srinivas S, Chang VT, Kasimis B: Asymptomatic mantle cell lymphoma in the trachea. Leukemia Lymphoma. 2009, 50: 651-652. 10.1080/10428190902718818.CrossRefPubMed
8.
Zurück zum Zitat Verde F, McGeehan A: Endotracheal involvement as an unusual extranodal site of recurrence from mantle cell lymphoma. Radiolology Case Report. 2008, 3: 194-Online Verde F, McGeehan A: Endotracheal involvement as an unusual extranodal site of recurrence from mantle cell lymphoma. Radiolology Case Report. 2008, 3: 194-Online
Metadaten
Titel
Acute dyspnoea and single tracheal localisation of mantle cell lymphoma
verfasst von
Jean-Christophe Ianotto
Adrian Tempescul
Jean-Richard Eveillard
Norbert André
Frederic Morel
Isabelle Quintin-Roué
Christian Berthou
Publikationsdatum
01.12.2010
Verlag
BioMed Central
Erschienen in
Journal of Hematology & Oncology / Ausgabe 1/2010
Elektronische ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-3-34

Weitere Artikel der Ausgabe 1/2010

Journal of Hematology & Oncology 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.